There are patents currently in place that prevent a company from making a generic Xeljanz (tofacitinib) product. However, this may change after the first patent for the drug expires in December 2020. Although tofacitinib is sometimes referred to as the generic name of Xeljanz, it is simply the active ingredient in the drug and not a generic version of it.
Xeljanz® (tofacitinib) is a prescription medication approved to treat rheumatoid arthritis. It comes as a pill that is usually taken twice a day.
Xeljanz is made by Pfizer Labs. It is protected from generic competition by patents that have not yet expired.
The first patent for Xeljanz is set to expire in December 2020. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or delay this exclusivity period, including such things as lawsuits or other patents for new Xeljanz uses. Once the patent expires, there may be several companies that manufacture a generic Xeljanz drug.
No -- tofacitinib is the active ingredient in Xeljanz, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.